TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Abbisko Cayman Limited ( (HK:2256) ).
Abbisko Therapeutics announced that it will present updated results from its phase 2 study of irpagratinib in combination with atezolizumab for advanced hepatocellular carcinoma (HCC) at the 2025 ESMO GI Congress. The study highlights a significant objective response rate and median progression-free survival, indicating the potential efficacy of this combination therapy for HCC patients, especially those with FGF19 overexpression. This development underscores Abbisko’s commitment to advancing cancer treatment options and could have implications for its market positioning and stakeholder interests.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the biopharmaceutical industry, focusing on the development of innovative therapies for cancer treatment. The company is particularly involved in researching and developing combination therapies for hepatocellular carcinoma (HCC) and other cancers, aiming to improve patient outcomes with novel treatment strategies.
Average Trading Volume: 5,452,665
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.15B
See more data about 2256 stock on TipRanks’ Stock Analysis page.